Chagas Clinical Research Platform

Chagas Clinical Research Platform

Chagas Clinical Research Platform logo

Founded: 2009, Uberaba, Brazil

508 members, from over 150 institutions and 24 countries

To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to facilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).

Chagas Platform Map

Enabling discussions among researchers is an important tool for the improvement of efficiency, diagnosis, and treatment.

Concepción Zúñiga Valeriano, Medical Doctor, Head of Chagas, Honduras

Newsletter N°13

Previous newsletters

Newsletter n°12, September 2022
English
Español
Português

Newsletter n°11, September 2021
English
Español
Português

Newsletter n°10, August 2020
English
Español
Português

Newsletter n°9, July 2019
English
Español
Português

Newsletter n°8, July 2018
English
Español
Português

Newsletter n°7, May 2017
English
Español
Português

Newsletter n°6, May 2016
English
Español

Newsletter n°5, April 2016
Español

Newsletter n°4, January 2015
Español

Newsletter n°3, April 2013
Español

Newsletter n°2, September 2012
English
Español 
Português

Newsletter n°1, September 2011
English
Español
Português

Platform updates

2019 Highlights

  • Two target product profiles initiated for special populations: children and people with suppressed immune systems
  • Development of a data-sharing platform with IDDO to collect and standardize clinical research data. This initiative will avoid duplication and contribute to accelerate development of better treatments
  • A workshop was organized in Argentina to streamline decision-making when evaluating therapeutic response in chronic Chagas disease

2018 Highlights

  • 95 members defined research priorities for the coming years and signed the Santa Cruz Letter, calling on governments, organizations, and donors to step up their efforts to control and eliminate Chagas as a public health problem.
  • 8 active clinical trial sites:
  • 117 people trained at 10 meetings, workshops, and seminars in Bolivia, Brazil, and the US: in ethics, Good Clinical Practice and Good Clinical Laboratory Practice for clinical trials, and in treatment access, communications, fundraising, advocacy, and finance.
  • Supported the publication of the Brazilian Clinical Protocols and Treatment Guidelines for Chagas Disease and PAHO’s 2018 publication of regional guidelines for Chagas disease.

2017 Highlights

  • 7 clinical trial sites were active: 3 in Bolivia for the Phase II proof-of-concept BENDITA trial (to assess safety and tolerability of benznidazole with reduced doses and treatment duration, and in combination with fosravuconazole) and 4 in Spain for the Phase II proof-of-concept study of fexinidazole to treat Chagas.
  • 161 people trained at 4 workshops/technical meetings in Colombia, Brazil, and the US.
  • Discussions promoted by the Chagas Platform in Brazil are supporting the ongoing changes of the Brazilian national guidelines for the treatment of Chagas disease.

2016 Highlights

  • Three clinical trial sites were active in Bolivia to support the Phase II proofof- concept BENDITA trial (benznidazole new doses improved treatment and associations).
  • At the Chagas Platform Annual Meeting, about 270 people were trained on key areas, including: qPCR validation and quality control for diagnosis and monitoring, discovery of new drugs, congenital Chagas disease, civil society movements, new research fields and guidelines for Chagas disease, new landscape for chronic patients, integrative therapy approach.

2015 Highlights

  • The number of CCRP members grew by 23%; about 40% of new members came from non-endemic countries.
  • The annual Chagas Clinical Research Platform meeting took place in Buenos Aires, Argentina in the context of National Chagas Week, with 230 attendees from, among others, national programmes, patient associations, research associations, research and clinical care centres, NGOs and pharmaceutical companies.

Contact the Chagas Clinical Research Platform